USA flag logo/image

An Official Website of the United States Government

IMMUNOLIPOSOME DELIVERY OF CHEMOTHERAPEUTICS

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
13734
Program Year/Program:
1990 / SBIR
Agency Tracking Number:
13734
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Vestar, Inc.
650 Cliffside Drive San Dimas, CA 91773
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 1990
Title: IMMUNOLIPOSOME DELIVERY OF CHEMOTHERAPEUTICS
Agency: HHS
Contract: N/A
Award Amount: $50,000.00
 

Abstract:

THIS PROJECT WILL DEVELOP MONOCLONAL ANTIBODY-TARGETED LIPOSOMES FOR THE PURPOSE OF DELIVERING CHEMOTHERAPEUTIC AGENTS. MONOCLONAL ANTIBODY RAISED AGAINST A TUMOR-SPECIFICSURFACE ANTIGEN WILL BE COVALENTLY COUPLED TO THE LIPOSOME SURFACE. THE LINKING CHEMISTRY TO BE USED HAS BEEN DEVELOPED TO SUIT SCALE-UP PHARMACEUTICAL PRODUCTION. THE LIPOSOME FORMULATION WILL HAVE A CHEMOTHERAPEUTIC AGENT DISSOLVED IN THE LIPOSOMAL MEMBRANE OR ENTRAPPED IN THE AQUEOUS INTERIOR OF THE LIPOSOME. EFFICACY WILL BE DETERMINED IN VITRO USING A TISSUE CULTURE ASSAY. EMPHASIS WILL BE PLACEDUPON SCALABLE FORMULATIONS AND MANUFACTURE PROTOCOLS IN THE TARGETED LIPOSOME DESIGN. DEMONSTRATION OF IN VITRO EFFICACY WILL LEAD TO PHASE II RESEARCH IN WHICH EMPHASIS WILL BE PLACED ON IN VIVO EFFICACY AND CHARACTERIZATION WITH RESPECT TO PHARMACOLOGY AND TOXICOLOGY OF THE LIPOSOMES. THE ULTIMATE GOAL IS TO DEVELOP A PRODUCT THAT TARGETS CYTOTOXIC AGENTS SPECIFICALLYTO TUMORS IN A FASHION THAT IS FAR SUPERIOR TO FREE DRUG OR NONTARGETED LIPOSOMAL DRUG.

Principal Investigator:

Sean M Sullivan
7143944000

Business Contact:

Small Business Information at Submission:

Vestar Inc
650 Cliffside Dr San Dimas, CA 91773

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No